The global influenza diagnostics market is anticipated to grow at a CAGR of around 8.3% during the forecast period (2021-2027). The rising prevalence of influenza diseases, the growing geriatric population which is more prone to this disease, and the rising demand for early diagnosis are the major factors driving the growth of the market. According to the estimates of the Centers for Disease Control & Prevention, in 2019-2020, flu caused 38 million illnesses, 400,000 hospitalizations, and 22,000 deaths in the US. The demand for point-of-care diagnosis solution and effective diagnostic kits has increased in the last few years due to growing concern and awareness for the treatments. To fulfil the market needs and customer demands, various authorities giving fund for the development of drugs and companies also taking initiatives by launching new molecular diagnostic kits.
Browse the full report description of "Global Influenza Diagnostic Market Size, Share & Trends Analysis Report By Test Type (Molecular Diagnostic Assays and Traditional Diagnostic Tests) By End-Users (Hospitals & Diagnostic Laboratories, Research & Academic Institutes, and Contract Research Organizations) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/influenza-diagnostics-market
In February 2021, Luminex Corp. has received a fund of $11.3 millionfrom the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). The fund was given to support the development and validation of a multiplex respiratory panel for flu A/B, respiratory syncytial virus (RSV), and SARS-CoV-2 targets on its Aries systems. Moreover, in June 2020, Cepheid announced the development of a next-generation Xpert Xpress SARS-CoV-2/Flu/RSV four-in-one test for the detection of SARS-CoV-2, Flu A, Flu B and RSV from a single patient sample. Similarly, in February 2020, Abbott Laboratories had launched a new inactivated quadrivalent vaccine for influenza that offers protection against four virus strains in India. Besides, these product developments, the Enormous Funding and Investment by the government for the R&D of influenza diagnostics further projected to create lucrative opportunities to the market.
Market Coverage
o By Test Type
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Influenza Diagnostics Market Report Segment
By Test Type
o RT-PCR
o LAMP
o NASBA
o SAMBA
o Rapid Influenza Diagnostic Tests (RIDT)
o Serological Assay
o Viral Culture
By End-User
Global Influenza Diagnostics Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/influenza-diagnostics-market